Breast Cancer | Specialty

CDK Inhibitors in Metastatic Hormone-Driven Breast Cancer

May 22nd 2017

O'Regan Covers Scope of ER+ and HER2+ Breast Cancer Advancements

May 22nd 2017

Ruth O’Regan, MD, provides insight on the evolving landscapes of ER-positive and HER2-positive breast cancers, and what regimens remain solid approaches for effective patient outcomes.

The Hunt for Biomarkers and Better Treatments in Advanced TNBC

May 21st 2017

In an OncLive Peer Exchange® discussion, experts in breast malignancies reviewed some exciting new developments in TNBC.

Dr. Piccart Discusses Biomarkers in Early Breast Cancer

May 19th 2017

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses biomarkers in early breast cancer.

Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

May 16th 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

May 9th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer.

FDA Approves Co-Packaging of Ribociclib With Letrozole for Metastatic Breast Cancer

May 9th 2017

The FDA has approved co-packaging of the oral medications ribociclib (Kisqali) and letrozole (Femara) for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.

Expert Weighs In on Neratinib Ahead of FDA Panel Review

May 9th 2017

Wolfgang Janni, MD, PhD, discusses toxicity management with neratinib and other agents for HER2-positive breast cancer, as well as emerging treatments and impactful trials in the field.

Dr. Carey on De-Escalating Treatments for Triple-Negative Breast Cancer

May 8th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

UVA Explores Same-Day Brachytherapy With Surgery for Early Breast Cancer

May 4th 2017

The University of Virginia Cancer Center has developed a new method for delivering radiation therapy along with less invasive surgery in a more precise and personalized manner.

Tripathy Highlights Neoadjuvant Advances in HER2+ Breast Cancer

May 3rd 2017

Debu Tripathy, MD, discusses current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.

HER2+ Breast Cancer Heterogeneity Calls for Combos

May 2nd 2017

Targeted therapies have improved outcomes for HER2-positive breast cancer, which is characterized by an aggressive tumor phenotype and lower overall survival. However, questions remain on how to predict which patients will benefit from neoadjuvant or extended HER2-targeted therapies and how to treat patients with triple-positive breast cancer.

Dr. Janni on the Future of Treatments for HER2-Positive Breast Cancer

May 2nd 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.

Dr. Osborne on Pertuzumab in HER2+ Breast Cancer

April 25th 2017

Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Abemaciclib Improves PFS in Phase III MONARCH 3 Breast Cancer Trial

April 24th 2017

Adding abemaciclib to letrozole or anastrozole improved progression-free survival compared with either aromatase inhibitor alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 3 study, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.

Veliparib Falls Short in Phase III NSCLC, TNBC Trials

April 21st 2017

Veliparib failed to meet the primary endpoint in phase III non-small cell lung cancer and triple-negative breast cancer trials.

Expert Weighs in on Future of HER2-Positive Breast Cancer Treatment

April 20th 2017

C. Kent Osborne, MD, sheds light on the current and future treatment of HER2-positive breast cancer.

Future Directions for Metastatic Breast Cancer

April 19th 2017

Unmet Needs for Metastatic Breast Cancer

April 19th 2017

Patient Selection for Eribulin in Breast Cancer

April 19th 2017